23 Results for "

tumor lymphatics

" in MedChemExpress (MCE) Product Catalog:
Products (23)

23 Results for "tumor lymphatics" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P1181A
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .
loading...
    loading...
Cat. No.: HY-152293
CAS No.: 1412453-70-3
Target:  

VEGFR ERK

Research Areas:  

Cancer

EVT801 is an orally active and selective inhibitor of VEGFR-3 (IC50=11 nM), which has antitumor effects. EVT801 inhibits not only VEGF-C-induced human endothelial cell proliferation, but also tumor (lymphatic) angiogenesis in tumor mouse models. EVT801 can reduce tumor hypoxia, immunosuppressive cytokines (CCL4, CCL5) and myeloid derived suppressor cells (MDSC) production. EVT801 has synergistic effect with immune checkpoint therapy (ICT), which improves ICT response rate and has better inhibitory effect on cancer mouse models . EVT801 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-P990608
CAS No.: 2921676-05-1
Synonyms: IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)

Target:  

CD3

Research Areas:  

Endocrinology Cancer

Alpitatug (IMC 3C5) is a fully human monoclonal antibody and also a VEGFR3 inhibitor. Alpitatug blocks renal lymphangiogenesis, prevents the formation of tubulointerstitial lymphatic vessels, and reduces the number of lymphatic vessels in rats. Alpitatug does not alter the proteinuria level, inflammatory cell infiltration, fibrosis markers or renal function parameters in proteinuric rats. Alpitatug can be used in research related to proteinuric nephropathy and advanced solid tumors .
loading...
    loading...
Cat. No.: HY-126395
CAS No.: 3536-49-0
Purity:  99.99%
Target:  

Fluorescent Dye

Research Areas:  

Others

Patent Blue V calcium salt is a triarylmethane dye used for tissue staining and lymphatic tracing, mainly applied by topical injection or eye drops. Patent Blue V calcium salt has affinity for specific tissues (such as corneal endothelium, lymphatic system), and stains the target structure by adsorption or binding, assisting in precise operation during surgery. Patent Blue V calcium salt is mainly used in ophthalmic surgery (such as graft staining for Descemet's membrane endothelial keratoplasty) and lymphatic drainage localization for sentinel lymph node biopsy of tumors .
loading...
    loading...
Cat. No.: HY-P1181
CAS No.: 868247-72-7
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .
loading...
    loading...
Cat. No.: HY-P4091
CAS No.: 945245-76-1
Research Areas:  

Cancer

LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics .
loading...
    loading...
Cat. No.: HY-P4089
CAS No.: 945245-82-9
Target:  

Peptides

Research Areas:  

Cancer

REA is a homing peptide that targets pre-cancerous tumor lymphatic vessels. REA homes to lymphatic vessels at the pre-cancerous tumor stage, but does not recognize tumor lymphatic vessels. REA can be used in pre-cancerous tumor research .
loading...
    loading...
Cat. No.: HY-N3968
CAS No.: 17303-67-2
Synonyms: GTN; (R)-(+)-Goniothalamin
Goniothalamin (GTN) is a styryl lactone. Goniothalamin exhibits insecticidal, anti-tumor and antibacterial activities. Goniothalamin induces cell cycle arrest and apoptosis in tumor cells. Goniothalamin acts as a larvicide against Culex quinquefasciatus larvae and as a cytotoxin against brine shrimp larvae. Goniothalamin functions as an antibacterial agent against Gram-positive and Gram-negative bacteria, and also acts as an antifungal agent against pathogens including Candida albicans, Trichophyton rubrum and Trichophyton mentagrophytes. Goniothalamin is applicable to research related to breast cancer, lymphatic filariasis, bacterial infections and fungal infections .
loading...
    loading...
Cat. No.: HY-P4088
CAS No.: 850859-24-4
Target:  

Peptides

Research Areas:  

Cancer

LyP-2 is a peptide that homes to tumor lymphatics. LyP2 homes to lymphatics of C8161 melanomas and cervical carcinomas and K14-HPV16 skin, but not to MDA-MB435 tumors, showing heterogeneity in the molecular markers of tumor cells and lymphatics .
loading...
    loading...
Cat. No.: HY-P4091A
Research Areas:  

Cancer

LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics .
loading...
    loading...
Cat. No.: HY-P4085
CAS No.: 945245-90-9
Target:  

Peptides

Research Areas:  

Cancer

AGR is a peptide. AGR recognizes lymphatic vessels in fully developed prostate tumors but not in the pre-malignant lesions .
loading...
    loading...
Cat. No.: HY-172271C
Target:  

Liposome

Research Areas:  

Cancer

DSPE-PEG3400-LyP-1 is a PEG compound which composed of DSPE and a nine residue peptide (LyP-1) (HY-P2526). LyP-1 targets tumor-associated lymphatic vessels and macrophages .
loading...
    loading...
Cat. No.: HY-187321A
Synonyms: DPPE-PEG2000-Cys-SRNLIDC
Research Areas:  

Cancer

DPPE-PEG2000-LyP-1 is a functionalized PEGylated lipid conjugate composed of three modular components: dipalmitoylphosphatidylethanolamine (DPPE) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DPPE-PEG2000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
loading...
    loading...
Cat. No.: HY-187332A
Synonyms: DSG-PEG2000-Cys-SRNLIDC
Research Areas:  

Cancer

DSG-PEG2000-LyP-1 is a functionalized PEGylated lipid conjugate composed of three modular components: distearoylglycerol (DSG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DSG-PEG2000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
loading...
    loading...
Cat. No.: HY-187243
Synonyms: DMG-PEG1000-Cys-SRNLIDC
Research Areas:  

Cancer

DMG-PEG1000-LyP-1 (DMG-PEG1000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DMG-PEG1000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
loading...
    loading...
Cat. No.: HY-187243A
Synonyms: DMG-PEG2000-Cys-SRNLIDC
Research Areas:  

Cancer

DMG-PEG2000-LyP-1 (DMG-PEG2000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DMG-PEG2000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
loading...
    loading...
Cat. No.: HY-187243B
Synonyms: DMG-PEG3400-Cys-SRNLIDC
Research Areas:  

Cancer

DMG-PEG3400-LyP-1 (DMG-PEG3400-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DMG-PEG3400-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
loading...
    loading...
Cat. No.: HY-187243C
Synonyms: DMG-PEG5000-Cys-SRNLIDC
Research Areas:  

Cancer

DMG-PEG5000-LyP-1 (DMG-PEG5000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DMG-PEG5000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
loading...
    loading...
Cat. No.: HY-187318
Synonyms: DOPE-PEG1000-Cys-SRNLIDC
Research Areas:  

Cancer

DOPE-PEG1000-LyP-1 (DOPE-PEG1000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DOPE-PEG1000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
loading...
    loading...
Cat. No.: HY-187318A
Synonyms: DOPE-PEG2000-Cys-SRNLIDC
Research Areas:  

Cancer

DOPE-PEG2000-LyP-1 (DOPE-PEG2000-Cys-SRNLIDC) is a functionalized PEGylated lipid conjugate composed of three modular components: dioleoylphosphatidylethanolamine (DOPE) as the lipid anchoring group, PEG, and LyP-1 peptide (CGNKRTRGC) (HY-P2526) as the terminal targeting/functional ligand. LyP-1 is a cyclic 9-amino acid peptide that specifically binds to p32/gC1qR protein, which is highly expressed on tumor-associated macrophages, lymphatic endothelial cells, and certain tumor cells. DOPE-PEG2000-LyP-1 can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against p32/gC1qR protein on the surface of lymphatic vessels, tumor-associated macrophages, and tumor cells.
loading...
    loading...